Non small cell lung cancer

Non small cell lung cancer

Last Reviewed : 12/24/2020
Non small cell lung cancer

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy is increasingly being used both pre-operatively (neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy).

We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.


Basic information: non-small-cell lung cancer medline plus lung cancer - non-small cell web md non-small-cell lung cancer university of maryland medical center non-small-cell lung cancer health line non-small cell lung cancer cleveland clinic non-small cell lung cancer


Advanced information: medscape non-small cell lung cancer medscape non-small cell lung cancer treatment & management lung types and staging of lung cancer metastatic non-small-cell lung cancer: esmo clinical practice guidelines by m. reck, s. popat, n. reinmuth, d. de ruysscher, k. m. kerr, s. peters ann oncol (2014) 25 (suppl 3): iii27-iii39.

society of nuclear medicine. "fdg pet evaluates immunotherapy for non-small cell lung cancer: molecular imaging is used to monitor a novel immunotherapy that aims to hamper tumors' ability to turn off cancer-fighting immune cells." sciencedaily. sciencedaily, 13 june 2016. . keg pathway non-small cell lung cancer - homo sapiens (human) upto date patient information: non-small cell lung cancer treatment; stage i to iii cancer (beyond the basics)


Research: : kuo c-h, lo c-y, chung f-t, lee k-y, lin s-m, et al. (2012) concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. plos one 7(3): e33226. doi:10.1371/journal.pone.0033226 zhu l, yu h, liu s-y, xiao x-s, dong w-h,chen y-n, et al. (2015) prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non–small cell lung cancer: a systematic review and meta-analysis. plos one 10(4): e0124230. doi:10.1371/journal.pone.0124230 mini review article front. oncol., 16 july 2014 | non-small cell lung carcinoma biomarker testing: the pathologist’s perspective by elisa brega and guilherme brandao pet-ct imaging in non-small cell lung carcinoma – a review of cases from a northern malaysia referral centre by joni bing fei teoh et al., iejsme 2008: 2 (2): 23-26 : hu x, pu k, feng x, wen s, fu x, guo c,et al. (2016) role of gemcitabine and pemetrexed as maintenance therapy in advanced nsclc:a systematic review and meta-analysis of randomized controlled trials. plos one 11(3):e0149247. doi:10.1371/journal.pone.0149247

desai c, mehta a, mishra d. usage patterns of biomarkers in non-small-cell lung cancer patients in india: findings from a systematic review and survey. lung india [serial online] 2014 [cited 2016 jul 1];31:249-59. available from: a five-gene signature and clinical outcome in non–small-cell lung cancer by hsuan-yu chen, et al., n engl j med 2007; 356:11-20january 4, 2007doi: 10.1056/nejmoa060096 prognostic and predictive value in kras in non–small-cell lung cancera review by kevin wood, md jama oncol. 2016;2(6):805-812. doi:10.1001/jamaoncol.2016.0405. emerging roles of nrf2 signal in non-small cell lung cancer by yijun tian et al., journal of hematology & oncology20169:14 doi: 10.1186/s13045-016-0246-5 nonsmall cell lung cancer by jean-paul sculier european respiratory review 2013 22: 33-36; doi: 10.1183/09059180.00007012 alpana s, javid j, mir r, masroor m, ahamad i, et al. (2013) tp53 is a mutational target in non small cell lung cancer patients and its pro/pro variant is potentially contributing to cancer susceptibility. j carcinogene mutagene 4:138. doi: 10.4172/2157-2518.1000138 non small cell lung cancer (nsclc): current status and future prospects by a.k. pathak, m. bhutani et al., indian j chest dis allied sci 2004; 46 : 191-203 gregory j. riely, jenifer marks, and william pao "kras mutations in non–small cell lung cancer", proceedings of the american thoracic society, vol. 6, no. 2 (2009), pp. 201-205.


Related videos: the pathophysiology of non-small cell lung cancer lung cancer staging non-small cell lung cancer (small cell lung carcinoma and non-small cell lung carcinoma) for usmle 2 non small cell lung cancer overview the role of immunotherapy in non small cell lung cancer nsclc nivolumab in non-small cell lung cancer vats lobectomy for the treatment of non-small cell lung cancer


Presentations/quiz/newspaper articles: medgadget lung cancer therapeutics market : development, size, share, growth and demand forecast to 2015 – 2021 daily record first new lung cancer drugs in 20 years approved for use in scotland
read more at the scotsman lung cancer treatments approved for scottish nhs

Please leave your comments:

Related Articles